Co-Diagnostics, Inc. (NASDAQ:CODX – Get Free Report) was the target of a large growth in short interest in October. As of October 30th, there was short interest totaling 981,329 shares, a growth of 49.5% from the October 15th total of 656,373 shares. Based on an average daily trading volume, of 438,760 shares, the short-interest ratio is presently 2.2 days. Currently, 10.5% of the company’s stock are sold short.
Co-Diagnostics Price Performance
Co-Diagnostics stock traded down $0.01 during midday trading on Wednesday, reaching $0.19. The company’s stock had a trading volume of 294,972 shares, compared to its average volume of 2,572,656. The stock’s 50-day simple moving average is $0.76 and its 200-day simple moving average is $2.06. Co-Diagnostics has a 52-week low of $0.17 and a 52-week high of $13.54. The stock has a market capitalization of $1.99 million, a P/E ratio of -0.02 and a beta of 3.15.
Co-Diagnostics (NASDAQ:CODX – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.24. Co-Diagnostics had a negative return on equity of 322.92% and a negative net margin of 5,530.54%. The business had revenue of $0.28 million for the quarter, compared to analyst estimates of $0.17 million.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on Co-Diagnostics
Institutional Trading of Co-Diagnostics
An institutional investor recently bought a new position in Co-Diagnostics stock. Susquehanna International Group LLP bought a new position in shares of Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 31,239 shares of the company’s stock, valued at approximately $97,000. Susquehanna International Group LLP owned about 0.85% of Co-Diagnostics at the end of the most recent quarter. 14.99% of the stock is owned by institutional investors.
About Co-Diagnostics
Co-Diagnostics, Inc. is a molecular diagnostics company that develops technologies and tests for detecting infectious diseases. Based in Salt Lake City, Utah, the company’s work centers on its proprietary CoPrimer technology, used to design assays for polymerase chain reaction (PCR) testing. Its products include PCR-based diagnostic tests and related instruments, including the Co-Dx PCR platform. The company has developed tests for a range of infectious diseases, with product availability and regulatory status varying by market.
See Also
- Five stocks we like better than Co-Diagnostics
- SpaceX’s Wild Ride Puts 2 Space Stocks and a Weekly-Payout ETF in Focus
- Palantir’s Political Controversy Is Hiding a Much Bigger Story
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
